Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine

Iodinated I-131 albumin

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Iodinated I-131 albumin key facts

Used for
MEGATOPE is indicated in adults for use in determinations of total blood and plasma volumes. (source)
Prescription or over the counter
Prescription (Rx)
Generic available
No generic listed by the FDA
Latest FDA recall
April 15, 2019 (Class II)

Sources: FDA label (September 1, 2023); FDA NDC Directory (October 30, 2026); FDA enforcement reports (October 27, 2026). Not medical advice.

Quick answers

What is Iodinated I-131 albumin used for?
The FDA-approved label (Megatope, Iso-Tex Diagnostics, Inc., September 1, 2023) says: “MEGATOPE is indicated in adults for use in determinations of total blood and plasma volumes.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the side effects of Iodinated I-131 albumin?
The “Adverse Reactions” section of the FDA label (Megatope, Iso-Tex Diagnostics, Inc., September 1, 2023) begins: “The following adverse reactions have been identified with the use of radioiodinated albumin products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Immune System Disorders: Hypersensitivity” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Iodinated I-131 albumin have a boxed warning?
No. None of the 2 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Iodinated I-131 albumin?
No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
Has Iodinated I-131 albumin been recalled?
FDA enforcement reports list 2 recalls of products of this medicine; the newest started April 15, 2019 (Class II). A recall usually concerns specific lots, not every product.
Who makes Iodinated I-131 albumin?
1 company lists prescription products of Iodinated I-131 albumin in the FDA NDC Directory, including Iso-Tex Diagnostics, Inc.

What Iodinated I-131 albumin is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

MEGATOPE is indicated in adults for use in determinations of total blood and plasma volumes.

— FDA label: Megatope, Iso-Tex Diagnostics, Inc., effective September 1, 2023. Read the full label on DailyMed →

Label quoted: the one for the most common form (injection, solution, intravenous), Megatope, Iso-Tex Diagnostics, Inc.; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.

The FDA has 2 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

0 of 2 FDA labels for this medicine have a boxed warning.

Iodinated I-131 albumin side effects

Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.

The following adverse reactions have been identified with the use of radioiodinated albumin products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Immune System Disorders: Hypersensitivity

— FDA label: Megatope, Iso-Tex Diagnostics, Inc., effective September 1, 2023. Read the full label on DailyMed →

Iodinated I-131 albumin dosage

Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.

Premedication Administer 10 drops of Strong Iodine Solution, USP (e.g., Lugol’s Solution) three times daily, beginning at least 24 hours before administration of MEGATOPE and continue for 1 week or 2 weeks thereafter to minimize the uptake of iodine-131. Recommended Dosage The recommended dose of MEGATOPE for total blood or plasma volume determination in adult patients is from 0.185 MBq to 1.85 MBq (5 microCi to 50 microCi) administered intravenously.

Read more of this section

When a procedure such as a blood volume is to be repeated, do not exceed 7.4 MBq (200 microCi) in any 1 week. Administration Instructions

  • Measure the patient dose using a suitable dose calibrator immediately prior to administration.
  • Use a shielded syringe for withdrawing and injecting MEGATOPE.
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. MEGATOPE is a colorless to very pale yellow solution. Do not use MEGATOPE if excessive coloration is present.
  • The expiration date given on the MEGATOPE vial label pertains to the stability of MEGATOPE and not to the radioactivity level. Blood Volume Determination Preparation of Reference Solution 1. Remove the amount from the vial to be used in the procedure identical in volume to the dose to be administered to the patient. 2. Prepare a reference solution using 0.9% Sodium Chloride Injection, USP as a diluent. The recommended dilution is 1:4,000 [Dilution Factor (DF) = 4,000]. 3. Determine the radioactivity concentration (net cpm/mL) of the reference solution. 4. Assay the reference solution and the blood samples (Step 3 of Administration of Dose) using the same geometric configuration. Administration of Dose 1. Inject the dose into a large vein in patient’s arm. Measure the residual radioactivity in the syringe and needle. 2. Do not reuse the syringe. Dispose the syringe in accordance with the US Nuclear Regulatory Commission or Agreement State regulations pertaining to the disposal of radioactive waste. 3. At 5 minutes and 15 minutes after injecting the dose, withdraw blood samples from the patient’s other arm with a sterile heparinized syringe. Calculation of Blood Volume 1. Take a known aliquot from each blood sample and determine radioactivity concentration in net cpm/mL. 2. Plot the 5-minute and 15- minute sample counts (net cpm/mL) on semilog graph paper using the average count value of each sample and determine the radioactivity concentration at injection time (zero time) by drawing a straight line through the 15-minute and 5-minute points to zero time. The x ordinate of the graph is the sample withdrawal time and the logarithmic y ordinate is radioactivity concentration in net cpm/mL. 3.

— FDA label: Megatope, Iso-Tex Diagnostics, Inc., effective September 1, 2023. This is part of the section. Read the full label on DailyMed →

Forms and how it is given

Dosage formsInjection, solution
RouteIntravenous
Prescription products2 in the FDA NDC Directory
Brand namesMegatope, Volumex

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • BLA: Biologics License Application: how a biologic medicine (made from living cells) is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
BLA017837
MEGATOPE
Iso TexFebruary 23, 1976 13, latest August 25, 2023
2023: Labeling · 1996: Manufacturing (CMC) · 1985: Manufacturing (CMC)

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.

  1. April 15, 2019 · Class II · Terminated · D-1136-2019

    Lack of Assurance of Sterility: environmental monitoring report exceeds limits, therefore sterility cannot be assured.

    Volumex (Iodinated I 131 Albumin) Injection USP, 25 uCi per 1 mL syringe, Rx Only, Manufactured for Daxor Corp., NY, NY; By: Iso-Tex Diagnostics, Inc.; NDC 50914-7720-8. — Iso-Tex Diagnostics, Inc

  2. March 11, 2019 · Class II · Terminated · D-1008-2019

    Lack of Assurance of Sterility: preliminary environmental monitoring report exceeds limits, therefore sterility cannot be assured.

    Volumex (Iodinated I 131 Albumin) Injection USP, 25 uCi per 1 mL syringe, Rx Only, Manufactured for Daxor Corp., NY, NY; By: Iso-Tex Diagnostics, Inc.; NDC 50914-7720-8. — Iso-Tex Diagnostics, Inc

What do the recall classes mean?

Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).

Official identifiers

SPL set ID of the quoted label62ca4278-8cc9-46b7-8f3c-303ce6a9c155
FDA labels (SPL)2
FDA applicationsBLA017837
Active ingredients (FDA)HUMAN SERUM ALBUMIN I-131

Next steps

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Megatope, Iso-Tex Diagnostics, Inc., effective September 1, 2023; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers